ArticleSisli Etfal Hastanesi tip bulteni2026
Clinical Characteristics and Pregnancy Outcomes of Thyrotoxicosis During Pregnancy: A Retrospective Observational Study.
Article in Sisli Etfal Hastanesi tip bulteni, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Thyrotoxicosis during pregnancy may be associated with adverse maternal and foetal outcomes; however, data comparing overt and subclinical thyrotoxicosis are limited. This study aimed to evaluate clinical characteristics, management, and pregnancy outcomes, and to explore associations with the achievement of euthyroidism in pregnant women with thyrotoxicosis. Methods: This retrospective study included 70 pregnant women diagnosed with thyrotoxicosis who presented to the outpatient clinics between 2022-2023. Patients were classified as having overt (n=34) or subclinical (n=36) thyrotoxicosis based on trimester-specific thyroid function tests. After excluding three patients with Graves' disease and one with a molar pregnancy, 31 overt and 35 subclinical gestational thyrotoxicosis patients were included in the analyses. Demographic features, clinical findings, biochemical parameters standardized as multiples of the upper limit of normal, treatment data, and pregnancy outcomes were obtained from medical records. Correlation analyses were performed to evaluate associations between gestational week and thyroid function tests. Results: The mean age was 29.6±5.3 years, and the mean GW at diagnosis was 10.7±3.0, with no significant differences between groups. At diagnosis, TSH was lower and fT4/fT3 higher in overt thyrotoxicosis compared to subclinical cases (p<0.05). Euthyroidism was achieved at a mean of 17.1±4.0 weeks, without significant group differences. Prior antithyroid drug therapy had been initiated in 18.2% of patients, mainly with PTU, with similar doses and treatment durations between groups. Pregnancy outcomes were available for 42 patients; 13 experienced complications (oligohydramnios, preterm delivery, pre-eclampsia, gestational diabetes, and intrauterine foetal death). Complication rates did not differ between groups, although anti-TPO positivity was more frequent among patients with complications (p=0.006). Correlation analyses showed that earlier gestational age at diagnosis was associated with higher thyroid hormone levels, while later achievement of euthyroidism correlated with lower TSH and higher peak fT3. Conclusion: Pregnancy outcomes were similar in overt and subclinical thyrotoxicosis. Gestational age at diagnosis was associated with thyroid hormone levels but not with maternal or foetal complications. Most patients achieved euthyroidism during pregnancy, and anti-TPO positivity was more common among those with pregnancy complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.